To date, two CD19-CAR-T cell therapies have been approved for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) [21]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.